Chrysalis Ventures
No summary available yet.
Chrysalis is the definition of a solid, no-drama regional fund that actually knows how to build businesses. They're not chasing unicorns or AI buzzwords - they want profitable, growing B2B software companies and they'll roll up their sleeves to help you get there. Bob Lowe genuinely knows operations and isn't afraid to challenge founders on their metrics. The downside? They're not going to lead your $50M Series C, and if you're building something that needs massive scale or network effects, they might not get it. But if you want smart money that won't micromanage and can actually help with enterprise sales strategy, they're underrated.
- —Best for: B2B SaaS founders who want operational help without the Silicon Valley circus
- —Watch out for: Limited ability to lead large later-stage rounds
- —Known for: Actually understanding unit economics and sustainable growth models
Chrysalis Ventures focuses on early-stage B2B software companies in the Southeast and Midwest, particularly those with strong recurring revenue models. They emphasize partnering with capital-efficient companies that can scale without massive funding rounds.
Series A and B enterprise software, with check sizes typically $2-8M. Heavy focus on SaaS, fintech, and healthcare IT companies in secondary markets outside Silicon Valley and NYC.
Former McKinsey consultant and serial entrepreneur who founded multiple software companies. Known for being hands-on with portfolio companies and having strong operational experience in scaling B2B businesses.
Former investment banker and private equity investor who joined Chrysalis to focus on later-stage growth investments. Has deep financial modeling expertise and helps with strategic initiatives.
Healthcare industry veteran who leads their healthcare IT investments. Former executive at several healthcare technology companies and brings valuable domain expertise and industry connections.
Have a specific question about Chrysalis Ventures?
Ask Bernie →